0001645113-20-000114.txt : 20200803 0001645113-20-000114.hdr.sgml : 20200803 20200803175342 ACCESSION NUMBER: 0001645113-20-000114 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200707 FILED AS OF DATE: 20200803 DATE AS OF CHANGE: 20200803 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Benaim Ely CENTRAL INDEX KEY: 0001632237 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37565 FILM NUMBER: 201070411 MAIL ADDRESS: STREET 1: C/O REXAHN PHARMACEUTICALS, INC. STREET 2: 15245 SHADY GROVE ROAD, SUITE 455 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NovoCure Ltd CENTRAL INDEX KEY: 0001645113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF BUSINESS PHONE: 44 (0)15 3475 6700 MAIL ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF FORMER COMPANY: FORMER CONFORMED NAME: Novocure Ltd DATE OF NAME CHANGE: 20150615 4 1 wf-form4_159649157316820.xml FORM 4 X0306 4 2020-07-07 0 0001645113 NovoCure Ltd NVCR 0001632237 Benaim Ely C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355 0 1 0 0 Chief Medical Officer Ordinary Shares 2020-07-07 5 A 0 E 325 50.405 A 30357 D Ordinary Shares 2020-07-31 4 S 0 341 76.388 D 30016 D The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2020 through June 30, 2020. This transaction is also exempt under Rule 16b-3(c). In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2020. Amended total to correct prior mathematical error. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. By: /s/ Steven Robbins, Attorney in Fact for Ely Benaim 2020-08-03